17th week of 2022 patent applcation highlights part 27 |
Patent application number | Title | Published |
20220127564 | RECOMBINANT YEAST HOST CELLS EXPRESSING CELL-ASSOCIATED HETEROLOGOUS PROTEINS - The present disclosure concerns recombinant yeast host cells expressing cell-associated heterologous proteins which are expressed during the propagation phase of the recombinant yeast host cells and processes for propagating same. The recombinant yeast host cells can be 5 used to make a yeast composition or a yeast product enriched in the heterologous proteins. | 2022-04-28 |
20220127565 | A Self-Assembling Short Amphiphilic Peptide And Related Methods And Uses - There is provided a self-assembly amphiphilic peptide having the formula (I): XYZ (I), wherein X is a polar moiety at the N-terminus; X and Z each independently has between 1 to 4 residues of aliphatic amino acids or analogs or derivatives thereof, and wherein the average degree of hydrophobicity of the residues in block Z is more than the average degree of hydrophobicity of the residues in block Y. Disclosed are compositions and hydrogel comprising the peptide thereof. Also disclosed are methods of treatment for tissue regeneration, wound healing and methods of culture of stem cells, tissues and organoids. | 2022-04-28 |
20220127567 | METHOD FOR PRODUCING ASTROCYTES - A method for producing astrocytes includes a step of dissociating an embryoid body into single cells and suspension-culturing the cells in a serum-free medium containing basic fibroblast growth factor (bFGF) and epidermal growth factor (EGF) to obtain a neural stem cell mass, and a step of dissociating the neural stem cell mass into single cells and adhesion-culturing the cells in a serum-free medium to obtain a cell population containing astrocytes. | 2022-04-28 |
20220127568 | COMPOSITIONS AND METHODS FOR GENERATING HAIR CELLS BY INHIBITING EPIGENETIC TARGETS - Provided are compositions and methods comprising an epigenetic agent and a Wnt agonist for increasing proliferation of cochlear supporting cells or vestibular supporting cells, and related methods of treating inner ear hearing or balance disorders. | 2022-04-28 |
20220127569 | METHODS OF PROMOTING THYMIC EPITHELIAL CELL AND THYMIC EPITHELIAL CELL PROGENITOR DIFFERENTIATION OF PLURIPOTENT STEM CELLS, RESULTING CELLS, AND USES THEREOF - The current disclosure provides for methods of promoting differentiation of pluripotent stem cells into thymic epithelial cells or thymic epithelial cell progenitors as well as the cells obtained from the methods, and solutions, compositions, and pharmaceutical compositions comprising such cells. The current disclosure also provides for methods of using the thymic epithelial cells or thymic epithelial cell progenitors for treatment and prevention of disease, generating organs, as well as other uses, and kits. | 2022-04-28 |
20220127570 | IMMUNE EFFECTOR CELL AND USE THEREOF - A geneticall engineered cell. The cell expresses an exogenous receptor binding to an antigen, and expresses increased RUNX3 or exogenous RUNX3. Also provided are a use of the cell and a method for treating tumors. | 2022-04-28 |
20220127571 | CELL POPULATIONS WITH IMPROVED PRODUCTION AND THERAPEUTIC CHARACTERISTICS - The present invention is directed to improved methods of preparing cells and compositions for therapeutic uses. | 2022-04-28 |
20220127572 | METHOD FOR LARGE-SCALE PRODUCTION OF ALLOSPECIFIC TYPE 1 REGULATORY TREGS (TR1) STABLE IN THE PRESENCE OF PROINFLAMMATORY CYTOKINES WITH THERAPEUTIC POTENTIAL IN TRANSPLANTATION - A methodology to obtain large numbers of allospecific human Tr1 lymphocytes in vitro differentiated with phenotype and suppressive function stability in presence of proinflammatory cytokines, by using donor tolerogenic dendritic cells (DC10) derived from donor monocytes and from a not related receptor (allogeneic) naîve T cells cocultures. The obtained cells with the present methodology are characterized by the expression of a Tr1 regulatory phenotype (CD4+, CD49b+, LAG-3+), being high IL-10 producers, and also they express additional co-inhibitory molecules as PD1, TIM-3, CD39, CTLA-4 y TIGIT. Moreover, the cellular product obtained by this methodology is able to maintain a stable phenotype and suppressive function in presence of proinflammatory cytokines (IL-1β, IL-6, IFN-γ y TNF-α). The numbers, purity, and stability of the Tr1 obtained by this methodology, make them great candidates for their use as therapeutic tools in transplantation. | 2022-04-28 |
20220127573 | PLATELET LYSATE PRODUCTION METHOD, PRODUCTION SYSTEM, AND BAG SET - Provided are a method for producing a platelet lysate, a production system, and a bag set capable of efficiently producing a platelet lysate with a simple device structure. According to the method for producing a platelet lysate, by which a platelet lysate (PL) that contains a growth factor contained in platelet is produced, buffy coat is collected from whole blood; the buffy coat (BC) is centrifuged to extract a supernatant, thereby collecting a platelet concentrate from which leukocyte has been removed; and, prior to freezing, the platelet concentrate is centrifuged to remove the supernatant, thereby preparing a highly concentrated platelet concentrate. The highly concentrated platelet concentrate is then frozen and thawed, and further centrifuged to recover the platelet lysate. | 2022-04-28 |
20220127574 | Universal Killer T-Cell - The present invention relates to a modified natural killer (NK) cell and its use in personalised medicine. The modified NK cells of the present invention are non-immunogenic, meaning that they are able to be administered to any recipient subject without being rejected by the host immune system (they are “universal”). In a first embodiment the non-immunogenic NK cells are modified to express CD3 to allow a T-cell Receptor (TcR) to be expressed. In a further embodiment the non-immunogenic NK cells are further modified to express a TcR together with the CD3 co-receptor. Co-expression of CD3 with a specific TcR results in the modified NK cells showing antigen-specific cytotoxicity towards target cells. Universal NK cells can thus be targeted against specific antigens, and may thus be used in personalised medicine, particularly in the field of oncology. | 2022-04-28 |
20220127575 | GENETICALLY MODIFIED HEMATOPOIETIC STEM AND PROGENITOR CELLS (HSPCS) AND MESENCHYMAL CELLS AS A PLATFORM TO REDUCE OR PREVENT METASTASIS, TREAT AUTOIMMUNE AND INFLAMMATORY DISORDERS, AND REBALANCE THE IMMUNE MILIEU AND DYSREGULATED NICHES - Provided are compositions comprising genetically modified hematopoietic stem and progenitor cells (HSPCs) and/or genetically modified mesenchymal cells, wherein the cells contain a vector comprising a transgene, as well as methods of producing the genetically modified HSPCs and genetically modified mesenchymal cells, and methods of treating or preventing cancer (e.g., metastasis) and neurodegenerative conditions, autoimmune disorders, and inflammatory disorders. | 2022-04-28 |
20220127576 | COMPOSITIONS AND METHODS FOR STEM CELL THERAPY - Provided herein are compositions and methods for improving outcome in stem cell transplantation. In particular, provided herein are compositions and methods for improving efficacy and reducing graft versus host disease in allogenic cell transplantation. | 2022-04-28 |
20220127577 | XENO-FREE GENERATION OF TISSUE-SPECIFIC PROGENITOR CELLS - The invention relates to purified, tissue-specific progenitors, methods of making and using such tissue-specific progenitors. | 2022-04-28 |
20220127578 | NOVEL EXOSOME PRODUCTION METHOD AND APPLICATION THEREOF - A method for producing exosomes is provided. The method includes culturing animal cells in a medium containing TNF-α and interferon-γ. This method is possible not only to increase production of exosomes to be isolated from a cell-derived conditioned medium, but also to exhibit an excellent effect of enhancing bioactivity of exosomes, such as increasing elastin synthesis of exosomes. | 2022-04-28 |
20220127579 | Use of Toll-Like Receptor 4 Agonists to Treat Inflammation and Tissue Injury - The disclosure relates to populations of educated macrophages and monocytes generated ex vivo or in vivo, and methods of making and using the same using lipid A aminoalkylglucosaminide phosphate molecules, such as CRX molecules or extracellular vesicles (EVs) from mesenchymal stromal cells (MSC) stimulated with CRX molecules. Also described are EVs and methods for making and using the same from MSCs exposed to CRX. | 2022-04-28 |
20220127580 | COMPOSITIONS AND METHODS FOR REPROGRAMING NON-HEPATOCYTE CELLS INTO HEPATOCYTE CELLS - A method for inducing non-hepatocytes into hepatocyte-like cells, wherein the non-hepatocytes are induced to express or overexpress hepatic fate conversion and maturation factors, cultured in somatic cell culture medium, hepatocyte expansion culture medium and 2C medium for a sufficient period of time to convert the non-hepatocyte cell into cells with hepatocyte-like properties, are provided. The iHeps induced according to the methods are also provided. | 2022-04-28 |
20220127581 | MULTICELLULAR INTEGRATED BRAIN TISSUE IN NEUROLOGICAL DISEASES - The present disclosure provides, in some embodiments, in vitro brain (miBRAIN) having functional and structural properties of in vivo brain as well as methods of identifying compounds capable of influencing brain function. | 2022-04-28 |
20220127582 | Proliferation Method - Provided is a method for efficiently proliferating an influenza virus serving as a material for vaccine in a host. | 2022-04-28 |
20220127583 | METHOD FOR PURIFICATION OF BACTERIOPHAGE PARTICLES - A method of recovering viable phage from, for example, a crude phage preparation such as a lysate resulting from amplification of phage in bacterial cell culture is disclosed. The method may be “universal”; that is, applicable to the purification of a broad range of phage species and strains. The phage product resulting from the method may have an acceptably low endotoxin titer (e.g. less than 500 EU/ml) and sufficiently high phage titer (e.g. >1×10 | 2022-04-28 |
20220127584 | Reactive persulfides mediate sulfur respiration in mitochondria via sulfide:quinone oxidoreductase - Method of using sulfide: quinone oxidoreductase (SQR) for persulfide-mediated generation of mitochondrial membrane potential and energy production, and method of using SQR for catalyzing proton and electron transfer from hydropersulfides to a mitochondrial electron transport chain. | 2022-04-28 |
20220127585 | DESIGN AND OPTIMIZATION OF TYPE IV BRAF INHIBITORS FOR THE TREATMENT OF MELANOMA - Inhibitory peptides for modifying RAF kinase protein dimerization are described. The peptides display a binding affinity for the dimer interface of a B-Raf, allowing for modification of RAF kinase dimerization, and inhibition of tumor growth. An embodiment of the disclosure is a peptide generated by modifying SEQ ID NO: 1, which corresponds to amino acids 503-521 of B-Raf kinase, e.g., cyclization, N-terminal capping, C-terminal capping, substitution of one or more amino acid residues, etc. The peptides disclosed herein include a modification to SEQ ID NO: 1 that can improve or otherwise alter binding affinity of the peptide to the dimer interface. | 2022-04-28 |
20220127586 | CGAS/DNCV-LIKE NUCLEOTIDYLTRANSFERASES AND USES THEREOF - The present invention is based, in part, on the discovery and characterization of the CD-NTase family of proteins, as well as compositions comprising CD-NTases, methods of producing nucleotide-based second messengers using such polypeptides, and methods of screening for modulators of the structure, expression, and/or activity of such polypeptides. | 2022-04-28 |
20220127587 | POLYMERASE ENZYME FROM PYROCOCCUS FURIOSUS - The present invention relates to a polymerase enzyme from | 2022-04-28 |
20220127588 | Modified Terminal Deoxynucleotidyl Transferase (TdT) Enzymes - The invention relates to engineered terminal deoxynucleotidyl transferase (TdT) enzymes or the homologous amino acid sequence of Polμ, Polβ, Polλ, and Polθ of any species or the homologous amino acid sequence of X family polymerases of any species and uses thereof. | 2022-04-28 |
20220127589 | Lactobacillus Mudanjiangensis Strains And Cellulase Derived Therefrom - The present invention in particular relates to the identification of novel | 2022-04-28 |
20220127590 | STREPTOCOCCUS BACTERIOPHAGE LYSINS FOR DETECTION AND TREATMENT OF GRAM POSITIVE BACTERIA - The present invention provides methods, compositions and articles of manufacture useful for the prophylactic and therapeutic amelioration and treatment of gram-positive bacteria, including | 2022-04-28 |
20220127591 | LYSOSOMAL ENZYMES MODIFIED BY CELL BASED GLYCOENGINEERING - The present invention relates to lysosomal enzymes modified by use of cell based methods, a compositions comprising a modified lysosomal enzyme, as well as methods for producing a modified lysosomal enzyme and therapeutic use of such modified lysosomal enzyme. In particular, the present disclosure relates to a modified lysosomal enzyme which has low Man6P and low exposed Mannose and high sialic acid content of alpha2,3 type enabling long circulation time and improved uptake into difficult-to-reach organs like heart, kidney and brain. | 2022-04-28 |
20220127592 | POLYPEPTIDE, USE AND METHOD FOR HYDROLYSING PROTEIN - The present invention relates to a method for producing a protein hydrolysate using a polypeptide having endopeptidase activity and a polypeptide having carboxypeptidase activity and the use of these enzymes for hydrolysing a protein substrate. In addition, the present invention relates to polypeptides having carboxypeptidase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides. | 2022-04-28 |
20220127593 | PRODUCING METHOD FOR ORGANISM-DERIVED MATERIAL, PRODUCING METHOD FOR PRODUCT, AND VOLTAGE APPLYING DEVICE - The producing method according to the disclosed technology is a producing method for an organism-derived material into which a bioactive substance has been introduced, the producing method comprising a step of causing a suspension containing the organism-derived material before the introduction of the bioactive substance and containing the bioactive substance to pass through a first electric field region having a first electric field intensity; and a step of causing the suspension to pass through a second electric field region having a second electric field intensity lower than the first electric field intensity after the suspension has passed through the first electric field region. The organism-derived material is a human-derived cell. | 2022-04-28 |
20220127594 | COMPOSITIONS AND METHODS FOR TREATING GLYCOGEN STORAGE DISEASE TYPE 1A - The invention provides compositions comprising novel adenosine base editors (e.g., ABE8) that have increased efficiency and methods of using base editors comprising adenosine deaminase variants for altering mutations associated with Glycogen Storage Disease Type 1a (GSD1a). | 2022-04-28 |
20220127595 | CONDITIONALLY ACTIVE BIOLOGICAL PROTEINS - Methods of generating conditionally active biologic proteins, in particular therapeutic or diagnostic proteins, which are more active at an aberrant condition than at a normal physiological condition. The methods include discovery methods using libraries of proteins and assays employing physiological concentrations of components of bodily fluids. The conditionally active biologic proteins may be further evolved, conjugated to other molecules, masked, reduced in activity by attaching a cleavable moiety. Criteria for selecting starting proteins for the discovery methods, as well as formats of the proteins are also disclosed. | 2022-04-28 |
20220127596 | Nucleic Acid Library Preparation Using Electrophoresis - Described herein are methods and systems for performing chemical or enzymatic reactions using electrophoresis. Devices, systems, and methods for preparing a library of tagged nucleic acid fragments from a target double-stranded nucleic acid using electrophoresis are also provided. Application of one or more electric fields causes molecules to migrate through the electrophoresis gel matrix. | 2022-04-28 |
20220127597 | HAPLOTAGGING - HAPLOTYPE PHASING AND SINGLE-TUBE COMBINATORIAL BARCODING OF NUCLEIC ACID MOLECULES USING BEAD-IMMOBILIZED TN5 TRANSPOSASE - The present invention relates to methods for producing solid supports. The present invention further provides a mixture of said solid supports for tagmentation of target DNA for DNA sequencing approaches, a corresponding kit comprising the same and methods employing said mixture of solid supports and/or kit. Specifically, methods for producing sequencing libraries and corresponding DNA sequencing methods for analyzing the generated sequencing libraries and tools used therein are provided. In particular, DNA In sequencing approaches allowing preservation of contiguity information of long DNA fragments even when using short read sequencing approaches are disclosed. A key concept of the present invention is to employ segmented barcodes, with every barcode segmented allowing for barcode error detection and correction on a segment level. Preferred barcode sequences employed are characterized in that they comprise no linker sequences or only linker sequences of one or two nucleotides in length between the barcode segments. | 2022-04-28 |
20220127598 | SPLINTED LIGATION ADAPTER TAGGING - A method comprises (a) providing single-stranded DNA; (b) ligating a first adapter to a 3′ end of the single-stranded DNA to form a once adapter ligated nucleic acid strand, the first adapter having a first protruding random sequence that is at least 3 bases long and that acts as a splint to join the single-stranded DNA with the first adapter; (c) ligating a second adapter to a 5′ end of the once adapter ligated nucleic acid strand to form a twice ligated nucleic acid strand, the second adapter having a second protruding random sequence that is at least 3 bases long and that acts as a splint to join the once adapter ligated nucleic acid strand with the second adapter; and (d) performing an amplification reaction on the twice ligated nucleic acid strand, thereby generating copies of the twice ligated nucleic acid strand. | 2022-04-28 |
20220127599 | METHOD FOR RECOVERING TWO OR MORE GENES, OR GENE PRODUCTS, ENCODING AN IMMUNORECEPTOR - The present invention is related to a method for recovering two or more genes, or gene products, or cDNAs, encoding for an immunoreceptor having two or more subunits, which two or more genes, or gene products, are comprised in a given source cell. The invention is further related to a method of creating a library of expressor cells, in which library each cell is capable of expressing two or more genes, or gene products, encoding for the subunits of the immunoreceptor. The invention is further related to a method of screening a library of expressor cells as created according to the above method, for one cell that expresses an immunoreceptor that has specificity for a given target molecule. | 2022-04-28 |
20220127600 | Methods of Detecting Analytes and Compositions Thereof - The invention relates to methods of detecting analytes in samples by generating analyte-based DNA libraries amenable for sequencing. The methods include the use of proximity probe pairs, each probe comprising an analyte binding domain and oligonucleotide domain. The methods further provide for integrated DNA and RNA library preparations and methods of making and uses thereof. The invention also provides compositions useful in the methods. | 2022-04-28 |
20220127601 | METHOD OF DETERMINING THE ORIGIN OF NUCLEIC ACIDS IN A MIXED SAMPLE - The present invention relates to a method for determining the origin of a nucleic acid fragment, or detecting a nucleic acid fragment, in a mixture of nucleic acid fragments, comprising the steps of: a) providing a mixture of fragmented nucleic acids stemming from a eukaryotic organism, b) preparing a sequencing library from the mixture of fragmented nucleic acids, c) hybridizing one or more probes to at least one location in said library wherein the mixture of fragmented nucleic acids comprises a hot spot for non-random fragmentation (HSNRF) and said probe covers said HSNRF, d) isolating one or more fragmented nucleic acids from the mixture that are bound by the one or more probes, e) amplifying and sequencing the enriched library, f) determining the size of a fragmented nucleic acid and/or, g) determining the start and/or stop position of the fragmented nucleic acid, and h) identifying the origin of the nucleic acid fragment by utilizing the information from steps (f) and/or (g), thereby determining the origin of/detecting the nucleic acid fragment. | 2022-04-28 |
20220127602 | GRNA TARGETING MIR-29B, AAV8-CRISPER/CAS9 SYSTEM AND USE THEREOF - The application provides a gRNA targeting miR-29b, an AAV8-CRISPR/Cas9 system and use thereof, belonging to the technical field of genetic engineering. The application provides a gRNA targeting miR-29b, which has a nucleotide sequence set forth in SEQ ID No.1. The gRNA shows strong specific editing ability to miR-29b at the cellular level, only has targeted editing effect on miR-29b without influence on miR-29a and miR-29c of the same family, and also shows higher editing efficiency, thus effectively inhibiting the expression of miR-29b. An AAV8-CRISPR/Cas9 system containing said gRNA targeting miR-29b. The use of gRNA targeting miR-29b or AAV8-CRISPR/Cas9 system in preparing drugs for treating muscle atrophy. | 2022-04-28 |
20220127603 | NOVEL CRISPR RNA TARGETING ENZYMES AND SYSTEMS AND USES THEREOF - The disclosure describes novel systems, methods, and compositions for the manipulation of nucleic acids in a targeted fashion. The disclosure describes non-naturally occurring, engineered CRISPR systems, components, and methods for targeted modification of a nucleic acid. | 2022-04-28 |
20220127604 | REVERSIR TM COMPOUNDS - The present invention relates, in general to agents that modulate the pharmacological activity of conjugated siRNAs. | 2022-04-28 |
20220127605 | NUCLEIC ACID CONJUGATE - The present invention provides a nucleic acid conjugate represented by the following formula 1: | 2022-04-28 |
20220127606 | NUCLEIC ACID DELIVERY COMPLEX - Provided are a complex that comprises a nucleic acid-containing nanoparticle and a hollow particle of a non-enveloped virus, a method for producing the complex, and a pharmaceutical composition comprising the complex. | 2022-04-28 |
20220127607 | METHODS AND MATERIALS FOR ACTIVATING AN INTERNAL RIBOSOME ENTRY SITE IN EXON 5 OF THE DMD GENE - The present invention relates to the delivery of oligomers for treating patients with a 5′ mutation in their DMD gene other than a DMD exon 2 duplication. The invention provides methods and materials for activating an internal ribosome entry site in exon 5 of the DMD gene resulting in translation of a functional truncated isoform of dystrophin. The methods and materials can be used for the treatment of muscular dystrophies arising from 5′ mutations in the DMD gene such as Duchenne Muscular Dystrophy or Becker Muscular Dystrophy. | 2022-04-28 |
20220127608 | P-ETHOXY NUCLEIC ACIDS FOR STAT3 INHIBITION - Provided herein are improved delivery systems for oligonucleotides, said delivery system comprising a liposome that comprises neutral phospholipids and a P-ethoxy oligonucleotide, which targets a STAT3-encoding polynucleotide. Methods of treating patients with said delivery systems are also provided. | 2022-04-28 |
20220127609 | ANTISENSE OLIGONUCLEOTIDES FOR NUCLEIC ACID EDITING - The invention relates to editing oligonucleotides (EONs) for binding to a target nucleic acid and recruiting an enzyme with nucleotide deamination activity to edit the target nucleic acid. The EONs carry phosphonoacetate internucleotide linkage modifications and/or unlocked nucleic acid (UNA) ribose modifications at specified positions and do not carry such modifications on positions that would lower nucleic acid editing efficiency. The selection of positions that should or should not carry a modification is based on computational modelling that revealed incompatibilities of the modifications with the enzyme with nucleotide deamination activity. | 2022-04-28 |
20220127610 | OLIGONUCLEOTIDES FOR USE IN THE TREATMENT OF DYSTROPHIC EPIDERMOLYSIS BULLOSA - The invention relates to antisense oligonucleotides (AONs) and the use thereof in the treatment of human disease. In particular the present invention is concerned with AONs suitable for the treatment of Dystrophic Epidermolysis Bullosa (DEB). More specifically, the invention relates to AONs that are capable of inducing exon 105 skipping from human COL7A1 pre-mRNA and that outperform—in exon 105 skipping efficiency—the AONs known from the prior art. The invention further relates to the use of these new AONs in the treatment of DEB in a patient carrying a mutation in exon 105 of the COL7A1 gene. | 2022-04-28 |
20220127611 | METHODS OF MODULATING RNA TRANSLATION - Provided are methods of modulating gene expression of a target RNA in a cell comprising (a) recruiting a modulation unit, wherein the modulation unit comprises an RNA binding protein (RBP), an exogenous RNA binding moiety, and a gene-editing agent; (b) delivering the modulation unit into the cell; and (c) detecting change in the target RNA translation, wherein the modulation unit modulates gene expression of the target RNA in the cell. | 2022-04-28 |
20220127612 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING AND TRANSLATION - Alternative splicing events in genes can lead to non-productive or less productive mRNA transcripts, and therapeutic agents which can target the alternative splicing events in genes can modulate the expression level of functional proteins in patients and/or inhibit aberrant protein expression. Provided herein are compositions and methods for modulating expression level of a target peptide sequence by modulating splicing of a pre-mRNA. Also provided herein are compositions and methods for treating a disease or condition caused by a deficient amount or activity of a functional target protein by modulating splicing of a pre-mRNA. | 2022-04-28 |
20220127613 | Functionally-Modified Oligonucleotides And Subunits Thereof - Functionally-modified oligonucleotide analogues comprising modified intersubunit linkages and/or modified 3′ and/or 5′-end groups are provided. The disclosed compounds are useful for the treatment of diseases where inhibition of protein expression or correction of aberrant mRNA splice products produces beneficial therapeutic effects. | 2022-04-28 |
20220127614 | COMPOSITIONS AND METHODS FOR TREATING COVID-19 - This disclosure is directed to inhibitory oligonucleotides, inhibitory peptides, compositions and methods for preventing or treating Coronavirus disease 2019 (COVID-19). In one aspect, the disclosure is directed to compositions that comprise inhibitory oligonucleotides against one or more SARS-CoV-2 virus genes. In another aspect, the disclosure is directed to compositions that comprise inhibitory peptides that inhibit SARS-COV-2 entry into cells. Another aspect of the disclosure is directed to gene therapy methods for treating COVID-19, and vectors for carrying out the same. Finally, the disclosure provides nutritional supplements to support human immunity and prevent or inhibit viral infections. | 2022-04-28 |
20220127615 | CORONAVIRUS IRNA COMPOSITIONS AND METHODS OF USE THEREOF - The present invention relates to RNAi agents, e.g., dsRNA agents, targeting the coronavirus genome. The invention also relates to methods of using such RNAi agents to inhibit expression of a coronavirus genome and to methods of treating or preventing a coronavirus-associated disease in a subject. | 2022-04-28 |
20220127616 | SAFE HARBOR LOCI - Provided herein are safe harbor loci and methods for identifying and using safe harbor loci to engineer cells to express transgenes. The safe harbor loci exhibit increased transgene knock-in efficiency and allow for increased, stable expression of transgenes in engineered cells. Guide ribonucleic acids (gRNAs) may be used for insertion of transgenes in the safe harbor loci. | 2022-04-28 |
20220127617 | TREATMENT OF CNS INJURY WITH RNAi THERAPEUTICS - Self-delivering PTEN RNA and methods of reducing PTEN expression are provided herein. Also provided are methods of treating spinal cord injury (SCI) and other neurotrauma with PTEN sdRNA. | 2022-04-28 |
20220127618 | KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF - The present invention relates to RNAi agents, e.g., double-stranded RNAi agents, targeting the ketohexokinase (KHK) gene, and methods of using such RNAi agents to inhibit expression of KHK and methods of treating subjects having a KHK-associated disorder, e.g., liver disease (e.g., fatty liver, steatohepatitis), dyslipidemia (e.g., hyperlipidemia, high LDL cholesterol, low HDL cholesterol, hypertriglyceridemia, postprandial hypertriglyceridemia), disorders of glycemic control (e.g., insulin resistance, diabetes), cardiovascular disease (e.g., hypertension, endothelial cell dysfunction), kidney disease (e.g., acute kidney disorder, tubular dysfunction, proinflammatory changes to the proximal tubules), metabolic syndrome, adipocyte dysfunction, visceral adipose deposition, obesity, hyperuricemia, gout, eating disorders, and excessive sugar craving. | 2022-04-28 |
20220127619 | MODULATORY POLYNUCLEOTIDES - The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of modulatory polynucleotides. | 2022-04-28 |
20220127620 | MICROBIAL PRODUCTION OF COMPOUNDS - Provide are modified host cells that are engineered to decrese expression of a product to undetectable levels in the presence of an exogenous agent, and increase expression of the product in the presence of another exogenous agent. The modified yeast strainshost cells do not express detectable levels of a precursor or substrate used to make the product. The product can be a cannabinoid or precursor thereof, and the substrate can be hexanoate. Also provided are methods for making a product using the modified host cells. The modified host cell can be a yeast strain, such as | 2022-04-28 |
20220127621 | FUSION PROTEINS AND FUSION RIBONUCLEIC ACIDS FOR TRACKING AND MANIPULATING CELLULAR RNA - Described herein are compositions, systems, methods, and kits utilizing RNA binding protein fusions, such as CRISPR-Cas protein fusions comprising a guide nucleotide sequence-programmable RNA binding protein, and a translation modifier protein. Also, described herein are compositions, systems, methods, and kits utilizing CRISPR-Cas associated RNA fusions comprising a guide nucleotide sequence-programmable RNA and an internal ribosome entry site (IRES). The compositions, systems, methods, and kits described herein are useful to upregulate or downregulate mRNA translation. | 2022-04-28 |
20220127622 | Compositions and Methods for Improving Base Editing - The invention features compositions and methods for modifying a polynucleotide (e.g., DNA) using a nucleobase editor comprising a first DNA binding protein domain that is catalytically inactive, a domain having base editing activity, and a second CDNA binding protein domain having nickase activity. The invention also features a fusion protein comprising a domain having base editing activity (e.g., cytidine deaminase or adenosine deaminase), and two nucleic acid programmable DNA binding protein domains (napDNAp), a first napDNAbp comprising nickase activity and a second napDNAbp that is catalytically inactive, where at least the two napDNAbps are joined by a linker, as well as related methods for using such base editors, and kits comprising the base editors. | 2022-04-28 |
20220127623 | FUSION PROTEINS HAVING MUTATED IMMUNOGLOBULIN HINGE REGION - A fusion protein having a non-immunoglobulin polypeptide having a cysteine residue proximal to the C terminal thereof, and an immunoglobulin component with a mutated hinge region is provided. The mutation comprises a point mutated site corresponding in position to the position in a native hinge region of the cysteine residue located nearest the cysteine residue of the non-Ig component. The distance from the cysteine residue of the non-immunoglobulin polypeptide and any remaining cysteine residues of the mutated hinge region is sufficient to prevent the formation of a disulphide bond therebetween. | 2022-04-28 |
20220127624 | Inducible Ammonia Production from a Symbiotic Diazotroph, Methods of Creation and Uses Thereof - The present disclosure describes systems and methods capable of fixing atmospheric nitrogen into bio-available nitrogenous compounds, including ammonia. Embodiments of the present disclosure are directed to synthetic DNA constructs encoding genes to allow release of bio-available nitrogenous compounds in nitrogen fixing diazotrophic organisms. Many of these constructs encode these genes in inducible and constitutive means, such that inducible embodiments can be activated at select times. Additional embodiments are directed to genetically engineered diazotrophs utilizing these constructs to produce bio-available nitrogenous compounds. Further embodiments are directed to methods to create these constructs and organisms as well as to use these constructs and organisms. | 2022-04-28 |
20220127625 | MODULATION OF REP PROTEIN ACTIVITY IN CLOSED-ENDED DNA (CEDNA) PRODUCTION - Provided herein are methods for producing DNA vectors comprising incubating a population of cells harboring the vector polynucleotide encoding a heterologous nucleic acid operatively positioned between a first and a second AAV inverted terminal repeat DNA polynucleotide sequence (ITRs), with at least one of the ITRs having nucleotide sequences corresponding to AAV wild type ITR in the presence of only a single species of Rep protein having at least DNA binding and DNA nicking functionality, under conditions effective and for a time sufficient to induce production of the DNA within the cells and harvesting and isolating the resultant DNA with the ITRs from the cells. | 2022-04-28 |
20220127626 | Methods for Altering Polypeptide Expression - The invention is directed to methods and metric suitable for use in modulating the expression of a polypeptide encoded by a nucleic acid sequence. In certain aspects, the invention also relates to methods for introducing modifications in a polypeptide, for example through substitution of one or more nucleic acids in an untranslated sequence or in a coding sequence of a nucleic acid sequence encoding a polypeptide to increase the expression of the polypeptide. | 2022-04-28 |
20220127627 | GUIDED MICROBIAL REMODELING, A PLATFORM FOR THE RATIONAL IMPROVEMENT OF MICROBIAL SPECIES FOR AGRICULTURE - The present disclosure provides guided microbial remodeling (GMR) methods for the rational improvement of plant-associated microbes to perform plant-beneficial functions. The GMR methods described herein allow for non-intergeneric genetic optimization of key regulatory networks within the microbes, which improve plant-beneficial functions over wild-type microbes but don't have the risks associated with transgenic approaches (e.g., unpredictable gene function, public and regulatory concerns, etc.). The present disclosure also provides remodeled microbes and compositions thereof. The utilization of remodeled microbes and compositions thereof will enable farmers to realize more productive and predictable crop yields without the nutrient degradation, leaching, or toxic runoff associated with traditional synthetically derived fertilizers. | 2022-04-28 |
20220127628 | A GENETICALLY MODIFIED LACTOBACILLUS AND USES THEREOF - The present invention relates to efficient delivery of anti-infective activity, immunomodulatory factors, or growth-promoting biomolecules directly to the digestive tract of an animal via a live delivery platform. The live delivery platform can be a genetically modified microorganism. Delivery can be accomplished with a | 2022-04-28 |
20220127629 | Chloride-Inducible Prokaryotic Expression System - The invention is directed to recombinant bacteria, a recombinant plasmid, a pharmaceutical composition and a kit as well as the use of a reconstitution medium comprising chloride ions to reconstitute the recombinant bacteria. | 2022-04-28 |
20220127630 | Brassica Plants Producing Elevated Levels of Polyunsaturated Fatty Acids - Provided herein are | 2022-04-28 |
20220127631 | LEGHEMOGLOBIN IN SOYBEAN - Soybean plants producing soybean seeds comprising leghemoglobin are produced by modifying the genome of the soybean plant. Soybean plants, soybean seeds and soy protein compositions comprising leghemoglobin are provided. Soybean plants, soybean seeds and soy protein compositions comprising leghemoglobin and additionally one or more of high oleic acid, low linolenic acid, high protein, low stachyose, low raffinose and low protease inhibitors are provided. Protein compositions comprising leghemoglobin, such as soy isolates and concentrates can be made from the soybean seeds. Additionally, methods for generating and using plants, seeds and protein compositions comprising leghemoglobin are disclosed. | 2022-04-28 |
20220127632 | LEGHEMOGLOBIN IN SOYBEAN - Soybean plants producing soybean seeds comprising leghemoglobin are produced by modifying the genome of the soybean plant. Soybean plants, soybean seeds and soy protein compositions comprising leghemoglobin are provided. Soybean plants, soybean seeds and soy protein compositions comprising leghemoglobin and additionally one or more of high oleic acid, low linolenic acid, high protein, low stachyose, low raffinose and low protease inhibitors are provided. Protein compositions comprising leghemoglobin, such as soy isolates and concentrates can be made from the soybean seeds. Additionally, methods for generating and using plants, seeds and protein compositions comprising leghemoglobin are disclosed. | 2022-04-28 |
20220127633 | HERBICIDE TOLERANT PLANTS AND PRODUCTION AND DETECTION OF SAME - The present invention refers to a plant or plant part comprising a polynucleotide encoding an herbicide tolerant IAA2 polypeptide having a deleted or disrupted degron tail region, the expression of said polynucleotide confers to the plant or plant part tolerance to synthetic auxin herbicides, such as 2,4-D. The present invention relates to methods and plants and that have a deleted or disrupted degron tail region of the IAA2 protein obtained by gene editing, transformation, mutagenesis, breeding, and the like. | 2022-04-28 |
20220127634 | METHODS AND COMPOSITIONS FOR PPO HERBICIDE TOLERANCE IN PLANTS - The invention relates to biotechnology and provides novel recombinant DNA molecules and engineered proteins for conferring tolerance to protoporphyrinogen oxidase-inhibitor herbicides. The invention also provides herbicide tolerant transgenic plants, seeds, cells, and plant parts containing the recombinant DNA molecules, as well as methods of using the same. | 2022-04-28 |
20220127635 | METHOD OF INCREASING RESISTANCE AGAINST SOYBEAN RUST IN TRANSGENIC PLANTS BY EXPRESSION OF A SUGAR TRANSPORTER - The present invention relates to an Lr67 allele differing from a soybean Lr67 wild type gene as defined herein. The allele unexpectedly conveys, intensifies or stabilizes fungal pathogen tolerance or resistance to a plant, seed, cell, or other plant part, most preferably against rusts of genus | 2022-04-28 |
20220127636 | FUNGAL RESISTANT PLANTS EXPRESSING RLK1 - The present invention relates to a method of increasing resistance against fungal pathogens of the order Pucciniales, preferably the family Phacopsoraceae, in plants and/or plant cells. This is achieved by increasing the expression of an RLK1 protein or fragment thereof in a plant, plant part and/or plant cell in comparison to wild type plants, wild type plant parts and/or wild type plant cells. Furthermore, the invention relates to transgenic plants, plant parts, and/or plant cells having an increased resistance against fungal pathogens, in particular, pathogens of the order Pucciniales, preferably the family Phacopsoraceae, and to recombinant expression vectors comprising a sequence that is identical or homologous to a sequence encoding an RLK1 protein. | 2022-04-28 |
20220127637 | TRANSCRIPTIONAL REGULATORY ELEMENT AND ITS USE IN ENHANCING THE EXPRESSION OF HETEROLOGOUS PROTEIN - Provided is a polynucleotide the polynucleotide can be used as a WXRE transcriptional regulatory element used to increase the protein expression level of a protein expression system. A protein expression vector or a protein expression systems comprising the above-mentioned WXRE transcriptional regulatory element as well as the use thereof are also provided. The use of the WXRE transcriptional regulatory element can increase the expression level of a heterologous protein greatly with its biological activity unchanged. | 2022-04-28 |
20220127638 | NON-HLA MATCHED HUMANIZED NSG MOUSE MODEL WITH PATIENT-DERIVED XENOGRAFT - The invention described herein provides non-HLA matched humanized mouse model (e.g., NSG mouse model) with patient-derived xenograft (PDX), as well as methods of making and using the same. | 2022-04-28 |
20220127639 | NON-HLA MATCHED HUMANIZED NSG MOUSE MODEL WITH PATIENT-DERIVED XENOGRAFT - The invention described herein provides non-HLA matched humanized mouse model (e.g., NSG mouse model) with patient-derived xenograft (PDX), as well as methods of making and using the same. | 2022-04-28 |
20220127640 | ARTIFICIAL MICRORNA PRECURSOR AND IMPROVED MICRORNA EXPRESSION VECTOR CONTAINING THE SAME - An isolated RNA molecule includes an artificial microRNA precursor comprising in the 5′→3′ direction: a first terminal oligonucleotide consisting of AGGCCR (SEQ ID NO: 1) or a nucleotide sequence in which one to three nucleotides in SEQ ID NO: 1 are substituted; a passenger strand oligonucleotide; a first central oligonucleotide consisting of CYG (SEQ ID NO: 2); a second central oligonucleotide consisting of a nucleotide sequence having at least 70% homology with UUGAAUAKAAAU (SEQ ID NO: 3); a third central oligonucleotide consisting of YGG (SEQ ID NO: 4); a guide strand oligonucleotide; and a second terminal oligonucleotide consisting of UGGAYYK (SEQ ID NO: 5) or a nucleotide sequence in which one to three nucleotides in SEQ ID NO: 5 are substituted. | 2022-04-28 |
20220127641 | Adeno-Associated Virus Delivery of CLN3 Polynucleotide - The present disclosure relates to recombinant adeno-associated virus (rAAV) delivery of a ceroid lipofuscinosis neuronal 3 (CLN3) polynucleotide. The disclosure provides rAAV and methods of using the rAAV for CLN3 gene therapy of the neuronal ceroid lipofuscinosis or CLN3-Batten Disease. | 2022-04-28 |
20220127642 | CONTROLLABLE GENOME EDITING SYSTEM - Provided herein are compositions and methods for genome editing and modification. In one embodiment, the composition comprises a regulatory gene expression construct that comprises a nucleic acid encoding an RNA comprising a sequence encoding a genome editing enzyme and a regulatory cassette operably linked to the sequence. In one embodiment, the regulatory cassette comprises a conditional exon and an aptamer domain which is capable of binding to an effector molecule to trigger a structural change of the RNA, thereby regulating splicing of the conditional exon and expression of the genome editing enzyme. | 2022-04-28 |
20220127643 | POLIOVIRUS RECEPTOR (PVR/CD155) KNOCKOUT CELLS DERIVED FROM RD (HUMAN RHABDOMYOSARCOMA) CELL LINE BY CRISPR - A modified polio virus receptor (PVR/CD155) gene including one or more mutations in exons selected from exons 2, 3 and 4 of poliovirus receptor (PVR/CD155) gene having SEQ ID No.1. More specifically, cell lines including the modified gene and method of producing the same using clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated protein 9 (CRISPR-Cas9) system. The cell line is refractory (non-permissive) to poliovirus and susceptible to most | 2022-04-28 |
20220127644 | CHIMERIC ANTIGEN RECEPTOR (CAR) NK CELLS AND USES THEREOF - Disclosed are plasmid and methods for genetically engineering NK cells using Adeno-associated viral (AAV) delivery of a CRISPR/CAS9 system. In some aspects, disclosed herein are method of using such engineering NK cells for treating cancers. | 2022-04-28 |
20220127645 | METHODS AND COMPOSITIONS FOR RNA-DIRECTED TARGET DNA MODIFICATION AND FOR RNA-DIRECTED MODULATION OF TRANSCRIPTION - The present disclosure provides a DNA-targeting RNA that comprises a targeting sequence and, together with a modifying polypeptide, provides for site-specific modification of a target DNA and/or a polypeptide associated with the target DNA. The present disclosure further provides site-specific modifying polypeptides. The present disclosure further provides methods of site-specific modification of a target DNA and/or a polypeptide associated with the target DNA The present disclosure provides methods of modulating transcription of a target nucleic acid in a target cell, generally involving contacting the target nucleic acid with an enzymatically inactive Cas9 polypeptide and a DNA-targeting RNA. Kits and compositions for carrying out the methods are also provided. The present disclosure provides genetically modified cells that produce Cas9; and Cas9 transgenic non-human multicellular organisms. | 2022-04-28 |
20220127646 | METHODS AND APPARATUS FOR HYDROGEN BASED BIOGAS UPGRADING - The present invention relates to an anaerobic process for biogas upgrading and hydrogen utilization comprising the use of acidic waste as co-substrate. In this process, H | 2022-04-28 |
20220127647 | METHOD FOR PREPARING NATURAL VANILLIN VIA BIOOXIDATION 4-METHYLGUAIACOL - A method for preparing natural vanillin via biooxidation of 4-methylguaiacol comprises (1) activating a strain and preparing a seed culture; (2) fermenting; (3) bioconversion; (4) adsorbing and eluting; and (5) concentrating and crystallizing. | 2022-04-28 |
20220127648 | GENETICALLY ENGINEERED YEAST YARROWIA LIPOLYTICA AND METHODS FOR PRODUCING BIO-BASED GLYCOLIC ACID - The present disclosure provides a method for genetically engineering | 2022-04-28 |
20220127649 | ENGINEERED CELLS FOR IMPROVED PRODUCTION OF CANNABINOIDS - The invention provides non-natural microbial organisms containing enzymatic pathways and/or metabolic modifications for enhancing synthesis of olivetolic acid, olivetolic acid derivatives and/or cannabinoids. | 2022-04-28 |
20220127650 | Process - A method for making 2-oxygenated decalins form isoprenoids catalysed with a squalene-hopene cyclase (SHC). A fragrance composition comprising (2S*,4aS*,8aR*)-5,5,8a-trimethyldecahydronaphthalen-2-yl acetate. | 2022-04-28 |
20220127651 | MICROBIOMES AND METHODS FOR PRODUCING MEDIUM-CHAIN FATTY ACIDS FROM ORGANIC SUBSTRATES - Microbiome compositions and uses thereof. The microbiome compositions include a set of microbes. The sets of microbes contain members of Lactobacillaceae, Eubacteriaceae, Lachnospiraceae, and Coriobacteriaceae. The number of individual physical microbes in the set constitutes a certain percentage of the total number of individual physical microbes in the microbiome composition. The microbiome compositions can be used for producing medium-chain fatty acids from organic substrates through anaerobic fermentation in a medium. The medium can include lignocellulosic stillage. | 2022-04-28 |
20220127652 | BACILLUS SUBTILIS NATTO AND METHOD FOR PRODUCING PROTEIN MK-7 - Provided is a | 2022-04-28 |
20220127653 | ENZYMATIC PRODUCTION OF MANNOSE - Disclosed herein are improved processes for making mannose including the step of converting the M6P to mannose, catalyzed by a M6PP, using enzymes with higher activities compared to M6PPs previously used in a process to produce mannose. | 2022-04-28 |
20220127654 | ALPHA-1,3-GLUCAN GRAFT COPOLYMERS - Compositions are disclosed herein comprising a graft copolymer that comprises: (i) a backbone comprising dextran that has been modified with about 1%-25% alpha-1,2 branches, and (ii) one or more alpha-1,3-glucan side chains comprising at least about 50% alpha-1,3 glycosidic linkages. Further disclosed are reactions for producing such graft copolymers, as well as their use in derivatives, films and various other applications. | 2022-04-28 |
20220127655 | Production of Steviol Glycosides in Recombinant Hosts - The invention relates to recombinant microorganisms and methods for producing steviol glycosides and steviol glycoside precursors. | 2022-04-28 |
20220127656 | APPARATUS, METHOD AND SYSTEM FOR SURFICIAL MOLD MONITOR BASED ON WEAK ELECTRICAL SIGNALS - Disclosed are apparatus, method and system for monitoring mold based on weak electrical signals. The apparatus comprises a mold collector, a power supply, a trans-impedance amplifier, and an analog-to-digital converter, wherein the mold collector is smeared with a trophoplasm, and a substrate of the mold collector has electrical conductivity, the power supply is used for applying a voltage to the substrate of the mold collector, the trans-impedance amplifier is used for amplifying a weak current generated from the substrate of the mold collector to a voltage signal, and the analog-to-digital converter is used for converting the voltage signal amplified by the trans-impedance amplifier into a digital signal for determining the quantity of molds. | 2022-04-28 |
20220127657 | A METHOD FOR DETECTING DORMANT OR CELL WALL DEFICIENT MYCOBACTERIUM SPECIES AND A METHOD AND MEDIUM FOR THE GROWTH PROMOTION OF DORMANT OR CELL WALL DEFICIENT FORMS OF MYCOBACTERIUM SPECIES - A method for detecting, in a blood or tissue sample, dormant or cell wall deficient | 2022-04-28 |
20220127658 | SYSTEMS AND METHODS FOR ULTRA-SPECIFIC AND ULTRA-SENSITIVE NUCLEIC ACID DETECTION - Methods according to aspects of the disclosure, compositions and kits therefore, include at least one, two, or three sets of amplification primers and hydrolysis probes with at least two separate corresponding readouts per set. According to aspects of the present disclosure, the at least two hydrolysis probes and associated pair of primers of each set are directed to opposite strands of an amplification product of the set. According to aspects of the present disclosure, one of the two hydrolysis probes in each set is directed to a first strand of the amplification product and therefore has a sequence complementary to the first strand of the amplification product and the second of the two hydrolysis probes in the set is directed to the second strand of the amplification product and therefore has a sequence complementary to the second strand of the amplification product. | 2022-04-28 |
20220127659 | Methods of Detecting Analytes - Localized detection of RNA in a tissue sample that includes cells is accomplished on an array. The array include a number of features on a substrate. Each feature includes a different capture probe immobilized such that the capture probe has a free 3′ end. Each feature occupies a distinct position on the array and has an area of less than about 1 mm | 2022-04-28 |
20220127660 | AN IMPROVED METHOD OF PREPARING CLINICAL SAMPLES FOR NUCLEIC ACID AMPLIFICATION - The present disclosure is a method of preparing a clinical sample comprising host cells, microbes, proteins and a polyanionic polymer nucleic acid amplification inhibitor. | 2022-04-28 |
20220127661 | COMPOSITIONS AND METHODS OF TARGETED NUCLEIC ACID ENRICHMENT BY LOOP ADAPTER PROTECTION AND EXONUCLEASE DIGESTION - Compositions and methods for enriching DNA from any loci of interest are provided. Endonuclease(s) such as RNA-guided nucleases Cpf1/Cas9 can cut the flanking regions of the gene of interest in, for example genomic DNA, followed by ligation of loop adapters. The loop adapters protect the gene of interest for subsequent digestion with one or more exonucleases. Multiple genes of interest can be digested and ligated with loop adapters at the same time. The undigested target sequence can be further purified by, for example, gel extraction using, for example, a commercial DNA purification kit. The enriched DNA can be used for sequencing. | 2022-04-28 |
20220127662 | NUCLEIC ACID-MEDIATED PATTERN REPLICATION AND METHOD OF MANUFACTURING 2-D MATERIAL USING THE SAME - Provided are the nucleic acid-mediated pattern replication and a method of manufacturing a 2-D material using the same. A method of manufacturing a 2-D material according to an embodiment may include preparing a first material having a first nucleic acid patterned on a surface thereof, bonding a linker-nucleic acid to the first nucleic acid, bonding the first nucleic acid and a second nucleic acid attached to a surface of a second material through the linker-nucleic acid and replicating a pattern of the first material to the surface of the second material, separating the first material, and applying a third material on a pattern replicated to the surface of the second material. | 2022-04-28 |
20220127663 | Nucleotide Reagent Solutions - A reagent solution includes water, a nucleotide, and tris(2-carboxyethyl)phosphine in a range of 0.5 μM to 1000 μM. The reagent solution can further include a non-ionic surfactant in an amount of 0.001% to 1% or a biocidal agent in an amount of 0.001% to 1%. The reagent solution can include salts, such as sodium chloride or magnesium sulfate. | 2022-04-28 |
20220127664 | MULTIPLEXED FLUOROMETRIC MEASUREMENTS WITH DROPLET PCR SYSTEMS - The present disclosure provides methods and compositions for detection of multiple nucleic acid targets in a single optical channel in a digital assay. In some cases, three or more nucleic acid targets may be detected in a single channel. Nucleic acid targets may be partitioned, amplified, used to generate signals, where each signal corresponds to a unique combination of nucleic acid targets in a partition. | 2022-04-28 |